290 related articles for article (PubMed ID: 31888250)
1. Novel Synthetic Approaches for Bisnaphthalimidopropyl (BNIP) Derivatives as Potential Anti-Parasitic Agents for the Treatment of Leishmaniasis.
Keskin E; Ucisik MH; Sucu BO; Guzel M
Molecules; 2019 Dec; 24(24):. PubMed ID: 31888250
[TBL] [Abstract][Full Text] [Related]
2. Anti-leishmanial activity of the bisnaphthalimidopropyl derivatives.
Tavares J; Ouaissi A; Silva AM; Lin PK; Roy N; Cordeiro-da-Silva A
Parasitol Int; 2012 Jun; 61(2):360-3. PubMed ID: 22155672
[TBL] [Abstract][Full Text] [Related]
3. Bisnaphthalimidopropyl derivatives as inhibitors of Leishmania SIR2 related protein 1.
Tavares J; Ouaissi A; Kong Thoo Lin P; Loureiro I; Kaur S; Roy N; Cordeiro-da-Silva A
ChemMedChem; 2010 Jan; 5(1):140-7. PubMed ID: 19937668
[TBL] [Abstract][Full Text] [Related]
4. Antileishmanial Drug Discovery: Synthetic Methods, Chemical Characteristics, and Biological Potential of Quinazolines and its Derivatives.
Sahu A; Kumar D; Agrawal RK
Antiinflamm Antiallergy Agents Med Chem; 2017; 16(1):3-32. PubMed ID: 28464778
[TBL] [Abstract][Full Text] [Related]
5. In vitro evaluation of bisnaphthalimidopropyl derivatives loaded into pegylated nanoparticles against Leishmania infantum protozoa.
Costa Lima S; Rodrigues V; Garrido J; Borges F; Kong Thoo Lin P; Cordeiro da Silva A
Int J Antimicrob Agents; 2012 May; 39(5):424-30. PubMed ID: 22398197
[TBL] [Abstract][Full Text] [Related]
6. Novel bisnaphthalimidopropyl (BNIPs) derivatives as anticancer compounds targeting DNA in human breast cancer cells.
Kopsida M; Barron GA; Bermano G; Kong Thoo Lin P; Goua M
Org Biomol Chem; 2016 Oct; 14(41):9780-9789. PubMed ID: 27722499
[TBL] [Abstract][Full Text] [Related]
7. Anticancer compounds as leishmanicidal drugs: challenges in chemotherapy and future perspectives.
Fuertes MA; Nguewa PA; Castilla J; Alonso C; Pérez JM
Curr Med Chem; 2008; 15(5):433-9. PubMed ID: 18288998
[TBL] [Abstract][Full Text] [Related]
8. Limitations of Current Therapeutic Options, Possible Drug Targets and Scope of Natural Products in Control of Leishmaniasis.
Tiwari N; Gedda MR; Tiwari VK; Singh SP; Singh RK
Mini Rev Med Chem; 2018; 18(1):26-41. PubMed ID: 28443518
[TBL] [Abstract][Full Text] [Related]
9. Repurposing of known drugs for leishmaniasis treatment using bioinformatic predictions, in vitro validations and pharmacokinetic simulations.
Bustamante C; Ochoa R; Asela C; Muskus C
J Comput Aided Mol Des; 2019 Sep; 33(9):845-854. PubMed ID: 31612362
[TBL] [Abstract][Full Text] [Related]
10. Drug resistance in leishmaniasis.
Croft SL; Sundar S; Fairlamb AH
Clin Microbiol Rev; 2006 Jan; 19(1):111-26. PubMed ID: 16418526
[TBL] [Abstract][Full Text] [Related]
11. 4-Arylamino-6-nitroquinazolines: Synthesis and their activities against neglected disease leishmaniasis.
Saad SM; Ghouri N; Perveen S; Khan KM; Choudhary MI
Eur J Med Chem; 2016 Jan; 108():13-20. PubMed ID: 26619389
[TBL] [Abstract][Full Text] [Related]
12. An update on small molecule strategies targeting leishmaniasis.
Kapil S; Singh PK; Silakari O
Eur J Med Chem; 2018 Sep; 157():339-367. PubMed ID: 30099256
[TBL] [Abstract][Full Text] [Related]
13. Palladium-mediated synthesis and biological evaluation of C-10b substituted Dihydropyrrolo[1,2-b]isoquinolines as antileishmanial agents.
Barbolla I; Hernández-Suárez L; Quevedo-Tumailli V; Nocedo-Mena D; Arrasate S; Dea-Ayuela MA; González-Díaz H; Sotomayor N; Lete E
Eur J Med Chem; 2021 Aug; 220():113458. PubMed ID: 33901901
[TBL] [Abstract][Full Text] [Related]
14. Do bismuth complexes hold promise as antileishmanial drugs?
Ong YC; Kedzierski L; Andrews PC
Future Med Chem; 2018 Jul; 10(14):1721-1733. PubMed ID: 29961352
[TBL] [Abstract][Full Text] [Related]
15. Conventional Versus Natural Alternative Treatments for Leishmaniasis: A Review.
Passero LFD; Cruz LA; Santos-Gomes G; Rodrigues E; Laurenti MD; Lago JHG
Curr Top Med Chem; 2018; 18(15):1275-1286. PubMed ID: 30277153
[TBL] [Abstract][Full Text] [Related]
16. Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages.
Borborema SE; Schwendener RA; Osso JA; de Andrade HF; do Nascimento N
Int J Antimicrob Agents; 2011 Oct; 38(4):341-7. PubMed ID: 21783345
[TBL] [Abstract][Full Text] [Related]
17. [Canine leishmaniasis: evolution of the chemotherapeutic protocols].
Oliva G; Foglia Manzillo V; Pagano A
Parassitologia; 2004 Jun; 46(1-2):231-4. PubMed ID: 15305724
[TBL] [Abstract][Full Text] [Related]
18. N, N', N″-trisubstituted guanidines: Synthesis, characterization and evaluation of their leishmanicidal activity.
do Espírito Santo RD; Velásquez ÁMA; Passianoto LVG; Sepulveda AAL; da Costa Clementino L; Assis RP; Baviera AM; Kalaba P; Dos Santos FN; Éberlin MN; da Silva GVJ; Zehl M; Lubec G; Graminha MAS; González ERP
Eur J Med Chem; 2019 Jun; 171():116-128. PubMed ID: 30913526
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis and Antileishmanial Activity of Naphthotriazolyl-4- Oxoquinolines.
Oliveira VG; Dos Santos Faiões V; Gonçalves GBR; Lima MFO; Boechat FCS; Cunha AC; de Andrade-Neto VV; de C da Silva F; Torres-Santos EC; de Souza MCBV
Curr Top Med Chem; 2018; 18(17):1454-1464. PubMed ID: 30277154
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapy of leishmaniasis part II: synthesis and bioevaluation of substituted arylketene dithioacetals as antileishmanial agents.
Pandey S; Suryawanshi SN; Gupta S; Srivastava VM
Eur J Med Chem; 2005 Aug; 40(8):751-6. PubMed ID: 15907348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
